(Q44440820)

3 December 2017

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. (English)

1 reference

3 December 2017

0 references

J A Kanis

1

1 reference

3 December 2017

E V McCloskey

2

1 reference

3 December 2017

H Johansson

3

1 reference

3 December 2017

O Strom

4

1 reference

3 December 2017

F Borgstrom

5

1 reference

3 December 2017

A Oden

6

1 reference

3 December 2017

National Osteoporosis Guideline Group

7

1 reference

3 December 2017

language of work or name

English

0 references

publication date

28 August 2008

1 reference

Osteoporosis International

3 December 2017

1 reference

3 December 2017

19

1 reference

3 December 2017

10

1 reference

3 December 2017

1395-1408

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-008-0712-1

3 December 2017

0 references

cites work

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-008-0712-1

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-008-0712-1

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-008-0712-1

Guidelines for diagnosis and management of osteoporosis

21 January 2018

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

FRAX and the assessment of fracture probability in men and women from the UK

1 reference

12 December 2020

A family history of fracture and fracture risk: a meta-analysis.

1 reference

12 December 2020

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

1 reference

12 December 2020

Diagnosis of osteoporosis and assessment of fracture risk

1 reference

12 December 2020

Alcohol intake as a risk factor for fracture

1 reference

12 December 2020

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study

1 reference

12 December 2020

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture

1 reference

12 December 2020

The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach

1 reference

12 December 2020

Body mass index as a predictor of fracture risk: a meta-analysis.

1 reference

12 December 2020

Assessment of fracture risk

1 reference

12 December 2020

Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study

1 reference

12 December 2020

Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study

1 reference

12 December 2020

Optimization of BMD measurements to identify high risk groups for treatment--a test analysis

1 reference

12 December 2020

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

12 December 2020

Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden

1 reference

12 December 2020

A meta-analysis of previous fracture and subsequent fracture risk

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

The burden of hospitalised fractures in Sweden

1 reference

12 December 2020

Requirements for DXA for the management of osteoporosis in Europe

1 reference

12 December 2020

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

1 reference

12 December 2020

A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk

1 reference

12 December 2020

Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors

1 reference

12 December 2020

BMD, clinical risk factors and their combination for hip fracture prevention

1 reference

12 December 2020

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

1 reference

12 December 2020

Intervention thresholds for osteoporosis in the UK

1 reference

12 December 2020

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

1 reference

12 December 2020

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

1 reference

12 December 2020

The cost-effectiveness of alendronate in the management of osteoporosis

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Cost-effective osteoporosis treatment thresholds: the United States perspective

1 reference

12 December 2020

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

1 reference

12 December 2020

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

1 reference

12 December 2020

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

Economic evaluation of interventions for osteoporosis

1 reference

12 December 2020

10.1007/S00198-008-0712-1

Identifiers

DOI

1 reference

3 December 2017

1 reference